Autoimmune thrombocytopenia induced by PEG-IFN-α plus ribavirin in hepatitis C

Platelets

Volumn 17, Issue 5, 2006, Pages 340-343

  Demirturk, Nese ^a,c   Cevik, Figen ^b   Demirdal, Tuna ^a   Aykin, Nevil ^b   Aslan, Vahap ^b  

^a AFYON KOCATEPE UNIVERSITY   (Turkey)

^b Social Insurance Institution Hospital   (Turkey)

^c AFYON KOCATEPE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Autoimmune thrombocytopenia; Chronic hepatitis C; Pegylated interferon; Standard interferon

Indexed keywords

DANAZOL; IMMUNOGLOBULIN G; PEGINTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; CASE REPORT; FEMALE; FOLLOW UP; GINGIVA BLEEDING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; PETECHIA; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; DANAZOL; DRUG CARRIERS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INTERFERON-ALPHA; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RIBAVIRIN;

HEPATITIS C VIRUS;

EID: 33747771032     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100600757935     Document Type: Article

References (19)

1. Dourakis SP, Deutsch M, Hadziyannis SJ. Immune thrombocytopenia and α-interferon therapy. J Hepatol 1996;25:972-975.
2. Raanani P, Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol 2002;107:133-144.
3. Zeuzem S. Treatment of hepatitis C virus infection. Schweiz Rundsch Med Prax 2005;94:721-726.
4. Sagir A, Wettstein M, Heintges T, Haussinger D. Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C. Dig Dis Sci 2002;47:652-653.
5. Medeiros BC, Seligman PA, Everson GT, Forman LM. Possible autoimmune thrombocytopenia associated with pegylated interferon-alpha2a plus ribavirin treatment for hepatitis C. J Clin Gastroenterol 2004;38:84-86.
6. Weitz IC. Treatment of immune thrombocytopenia associated with interferon therapy of hepatitis C with the anti-CD20 monoclonal antibody, Rituximab. Am J Hematol 2005;78:138-141.
7. Sevastianos VA, Deutsch M, Dourakis SP, Manesis EK. Pegylated interferon-2b-associated autoimmune thrombocytopenia in a patient with chronic hepatitis C. Am J Gastroenterol 2003;98:706-707.
8. Lambotte O, Gelu-Simeon M, Maigne G, Kotb R, Buffet C, Delfraissy JF, Goujard C. Pegylated interferon alpha-2a-associated life-threatening Evans' syndrome in a patient with chronic hepatitis C. J Infect 2005;51:113-115.
9. Dumoulin FL, Leifeld L, Sauerbruch T, Spengler U. Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Biomed Pharmacother 1999;53:242-254.
10. Semple JW, Freedman J. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood 1991;78:2619-2625.
11. Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW. Peginterferon alone or with ribavirin enhances HCV-specific CD4T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 2002;123:1070-1083.
12. Ahn YS, Rocha R, Mylvaganam R, Garcia R, Duncan R, Harrington WJ. Long term danazol therapy in autoimmune thrombocytopenia, unmaintained remission and age-dependent response in women. Ann Intern Med 1989;111:723-729.
13. Nagamine T, Ohtuka T, Takehara K, Arai T, Takagi H, Mori M. Thrombocytopenia associated with hepatitis C viral infection. J Hepatol 1996;24:135-140.
14. Garcia-Suarez J, Burgaleta C, Hernanz N, Albarran F, Tobaruela P, Alvarez-Mon M. HCV-associated thrombocytopenia: Clinical characteristics and platelet response after recombinant alpha2b-interferon therapy. Br J Haematol 2000;110:98-103.
15. Rajan SK, Espina BM, Liebman HA. Hepatitis C virus-related thrombocytopenia: Clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. Br J Haematol 2005;129:818-824.
16. Ide T, Kumashiro R, Hino T, Murashima S, Ogata K, Koga Y, Sata M. Short term and two-step interferon therapy for chronic hepatitis C patients with low HCV RNA levels. Hepatol Res 2002;22:145-151.
17. Fried MW. Clinical application of hepatitis C virus genotyping and quantitation. Clin Liver Dis 1997;1:631-646.
18. Bozdayi G, Rota S, Verdi H, Derici U, Sindel S, Bali M, Basay T. The presence of hepatitis C virus (HCV) infection in hemodialysis patients and determination of HCV genotype distribution. Mikrobiyol Bul 2002;36:291-300.
19. Abacioglu YH, Davidson F, Tuncer S, Yap PL, Ustacelebi S, Yulug N, Simmonds P. The distribution of hepatitis C virus genotypes in Turkish patients. J Viral Hepat 1995;2:297-301.